Rep. Castor Introduces the Advancing Safe Medications for Moms and Babies Act to Study Drug Safety
This bill is in the early stages of the legislative process and is currently sitting in the House Committee on Energy and Commerce. Since May 3, 2026, no further action has been taken by the committee. It is common for bills to stall at this stage without receiving a vote.
The bill has support from both parties and addresses a major gap in medical knowledge, but most bills face a long road through committees before becoming law.
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 1117 (118th), which died when its Congress ended.
H.R. 1117 (118th) →Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
This bill directly targets pregnant and lactating women by requiring that FDA regulations be updated to include them in clinical research, launching an education campaign so they can find and enroll in studies, and prioritizing NIH research on drugs they commonly use. Over time, this could lead to much better safety information about medications taken during pregnancy and breastfeeding, filling a major gap in medical knowledge that currently forces doctors to prescribe drugs without solid evidence of their effects on mothers and babies.
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Advancing Safe Medications for Moms and Babies Act of 2026
Analysis generated by AI. Always verify with official sources.